In a statement released March 10, Novo Nordisk said it initially received inspectional observations from the FDA in February 2025, and that it has been working diligently to address those observations ever since. In the statement on Tuesday, the drugmaker acknowledged it received the warning letter and that it welcomes further dialogue with the US FDA. The company said it is working diligently to address the concerns of the FDA
As ACSL4 gains traction as a therapeutic target in oncology, its role in activating the ferroptosis mechanism presents a novel strategy for treating tumors, especially those resistant to conventional chemotherapy or adept at evading apoptosis [43]
You burn more
After-sales support evaluation should cover technical assistance for market authorization, reformulation services for regional compliance adjustments, and inventory management flexibility
Mnzel, T., Daiber, A., Ullrich, V
Towards a brighter future for millions of patients Given the growing global prevalence of T2D and obesity, the implementation of sublingual formulations could have profound implications for public health
